Li Mei, Zhang Zhongyi, Li Mingzhou, Chen Zhe, Tang Weizhu, Cheng Xiang
Department of Oncology, The First Affiliated Hospital of the Hubei Three Gorges Polytechnic, Yiling Hospital of Yichang, Yichang, Hubei, China.
The Second Affiliated Hospital of Guilin Medical University, Guilin Medical University, Guilin, Guangxi, China.
Front Genet. 2023 Jul 26;14:1181320. doi: 10.3389/fgene.2023.1181320. eCollection 2023.
Colon adenocarcinoma (COAD) is a common malignancy with high morbidity and mortality rates. The immune system plays a crucial role in CRC development and progression, making it a potential therapeutic target. In this study, we analyzed transcriptomic data from CRC patients to investigate immune infiltration and identify potential therapeutic targets. we used CIBERSORT to analyze the immune infiltration in COAD samples and found that the high infiltration of M2 macrophages and neutrophils was associated with poor prognosis. Next, we identified NR4A1 as a potential therapeutic target based on its protective effect in two predict models. Using cancer therapeutics response analysis, we found that high expression levels of NR4A1 were sensitive to OSI-930, a tyrosine kinase inhibitor with anti-tumor effects. Our findings suggest that targeting NR4A1 with OSI-930 may be a promising therapeutic strategy for COAD patients with high levels of immune infiltration. However, further studies are needed to investigate the clinical efficacy of this approach.
结肠腺癌（COAD）是一种常见的恶性肿瘤，发病率和死亡率都很高。免疫系统在结直肠癌的发生和发展中起着关键作用，使其成为一个潜在的治疗靶点。在本研究中，我们分析了结直肠癌患者的转录组数据，以研究免疫浸润并确定潜在的治疗靶点。我们使用CIBERSORT分析COAD样本中的免疫浸润，发现M2巨噬细胞和中性粒细胞的高浸润与预后不良有关。接下来，基于NR4A1在两个预测模型中的保护作用，我们将其确定为一个潜在的治疗靶点。通过癌症治疗反应分析，我们发现NR4A1的高表达水平对OSI-930敏感，OSI-930是一种具有抗肿瘤作用的酪氨酸激酶抑制剂。我们的研究结果表明，用OSI-930靶向NR4A1可能是免疫浸润水平高的COAD患者一种有前景的治疗策略。然而，需要进一步研究来调查这种方法的临床疗效。
